Bayer and NHCS to set up Centre of Excellence for Explorative Cardiovascular Studies 17:03 | 18/12/2020
Bayer and National Heart Centre Singapore today announced that they have entered into a 5-year collaboration agreement to set up a Center of Excellence for Explorative Cardiovascular Studies.
Bayer and NHCS will collaborate on forming a better understanding of cardiovascular diseases in Asian patients. Photo: Freepik
Bayer and National Heart Centre Singapore (NHCS) will establish a Center of Excellence for Explorative Cardiovascular Studies with the aim of boosting patient-centricity in research and development (R&D) and improving treatment outcomes in cardiovascular disease (CVD) management.
Combining NHCSâ vast experience in managing Asian CVD patients and clinical research and Bayerâs expertise in pharmaceutical R&D, the centre will generate and integrate high-quality patient data into early clinical research which will allow the b
E-Mail
Leveraging on Asian patient data, the 5-year collaboration aims to boost patientcentricity in R&D, leading to improved treatment outcomes in cardiovascular disease (CVD) management.
The Center will generate and integrate high quality patient data into early clinical research to inform future targeted therapies for CVDs.
Bayer will contribute S$5.4million (approx. EUR 3.4 million) towards this
collaboration.
Singapore, December 17, 2020 - Bayer and National Heart Centre Singapore (NHCS) today announced that they have entered into a 5-year collaboration agreement to set up Center of Excellence for Explorative Cardiovascular Studies (hereinafter Center ) with the aim of boosting patient-centricity in research and development (R&D) and improving treatment outcomes in cardiovascular disease (CVD) management. Combining NHCS vast